Genomic Health Inc (GHDX)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Genomic Health Inc (GHDX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013821
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer test and Oncotype SEQ Liquid Select liquid biopsy mutation panel. Genomic Health develops these products using its Oncotype IQ Genomic Intelligence Platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company has operations in North America, Europe and Asia through direct offices, subsidiaries and distributors. Genomic Health is headquartered in Redwood City, California, the US.

Genomic Health Inc (GHDX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Genomic Health Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Genomic Health Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Genomic Health Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Genomic Health Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Genomic Health Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Genomic Health Inc, Medical Equipment, Deal Details 12
Venture Financing 12
Epic Sciences Raises USD40 Million in Series D Venture Financing 12
InVitae Raises USD120 Million in Series F Venture Financing 14
Invitae Raises US$40 Million In Series E Financing 16
Partnerships 17
Genomic Health Enters into Licensing Agreement with Biocartis 17
New England Biolabs Enters into Licensing Agreement with Genomic Health for Ribosomal RNA Depletion Technology 18
Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 19
NewBridge Pharma Enters Into Licensing Agreement With Genomic Health For Oncotype DX Tests 21
Genomic Health and Epic Sciences Enter into Distribution Agreement 22
Philips Electronics Enters into Agreement with Genomic Health 23
Specialised Therapeutics Enters Into Distribution Agreement With Genomic Health For Oncotype DX Test 24
Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 25
Equity Offering 26
Genomic Health Files Registration Statement For Public Offering Of Shares To Raise Up To US$334 Million 26
Genomic Health Inc – Key Competitors 27
Genomic Health Inc – Key Employees 28
Genomic Health Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 08, 2017: Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress 30
Aug 01, 2017: Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress 32
May 09, 2017: Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress 34
Feb 14, 2017: Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook 36
Nov 01, 2016: Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results 38
Aug 02, 2016: Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance 40
May 04, 2016: Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results 42
Feb 10, 2016: Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results 44
Jan 08, 2016: Genomic Health Announces Preliminary 2015 Revenue and Confirms 2016 Growth Expectations 46
Product News 47
Jun 02, 2017: Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX Tests to Optimize Outcomes in Patients Across Cancer Types 47
May 30, 2017: Genomic Health Announces Presentation of Eight Oncotype DX Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types 49
Sep 28, 2016: Genomic Health Reinforces Global Leadership in Genomic-based Diagnostics with Presentation of Nine Personalized Medicine Studies Conducted in Six Countries at ESMO 2016 Congress 52
03/11/2016: Genomic Health Announces Five-year Outcomes from International ‘PlanB’ Study Demonstrating the Clinical Utility of Oncotype DX in Node-positive and High-risk Node-negative Breast Cancer 55
03/09/2016: German National Cancer Guidelines Distinguish Oncotype DX as First and Only Multi-gene Breast Cancer Test with 1A Level of Evidence 57
03/01/2016: Journal of Clinical Oncology Publishes Prospective Outcomes Results from Large International Trial Using Oncotype DX 58
01/11/2016: Genomic Health Announces Plans to Launch Liquid Biopsy Mutation Panel in 2016 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Genomic Health Inc, Medical Equipment, Key Facts, 2016 2
Genomic Health Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Genomic Health Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Genomic Health Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Genomic Health Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Genomic Health Inc, Deals By Market, 2011 to YTD 2017 9
Genomic Health Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Epic Sciences Raises USD40 Million in Series D Venture Financing 12
InVitae Raises USD120 Million in Series F Venture Financing 14
Invitae Raises US$40 Million In Series E Financing 16
Genomic Health Enters into Licensing Agreement with Biocartis 17
New England Biolabs Enters into Licensing Agreement with Genomic Health for Ribosomal RNA Depletion Technology 18
Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 19
NewBridge Pharma Enters Into Licensing Agreement With Genomic Health For Oncotype DX Tests 21
Genomic Health and Epic Sciences Enter into Distribution Agreement 22
Philips Electronics Enters into Agreement with Genomic Health 23
Specialised Therapeutics Enters Into Distribution Agreement With Genomic Health For Oncotype DX Test 24
Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 25
Genomic Health Files Registration Statement For Public Offering Of Shares To Raise Up To US$334 Million 26
Genomic Health Inc, Key Competitors 27
Genomic Health Inc, Key Employees 28
Genomic Health Inc, Other Locations 29
Genomic Health Inc, Subsidiaries 29

★海外企業調査レポート[Genomic Health Inc (GHDX)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genetic Technologies Ltd (GTG):企業の財務・戦略的SWOT分析
    Genetic Technologies Ltd (GTG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Kesko Corp (KESKOA):企業の財務・戦略的SWOT分析
    Kesko Corp (KESKOA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Western Gas Partners, LP:企業のM&A・事業提携・投資動向
    Western Gas Partners, LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Western Gas Partners, LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Living Cell Technologies Ltd (LCT):医療機器:M&Aディール及び事業提携情報
    Summary Living Cell Technologies Ltd (LCT) is a biotechnology company that develops cell-based therapeutics for the treatment of neurological diseases, diabetes, and stroke and hearing loss. It focuses on discovering regenerative treatments which restore function using naturally occurring cells. LCT …
  • McGill University-製薬・医療分野:企業M&A・提携分析
    Summary McGill University (McGill) is a research based educational institute. The university offers undergraduate, graduate and post-graduate courses. It provides academic courses across various disciplines including agricultural and environmental sciences, arts, dentistry, education, engineering, l …
  • Concord Medical Services Holdings Ltd (CCM):製薬・医療:M&Aディール及び事業提携情報
    Summary Concord Medical Services Holdings Ltd (CMS) is a diagnostic imaging center that offers clinical support services and laboratory services. The center offers radiotherapy and diagnostic imaging equipment services such as head gamma knife systems, body gamma knife systems and linear accelerator …
  • Acadia Pharmaceuticals Inc (ACAD):企業の財務・戦略的SWOT分析
    Acadia Pharmaceuticals Inc (ACAD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Penta-Ocean Construction Co Ltd:戦略・SWOT・企業財務分析
    Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • United Company RUSAL Plc:企業の戦略・SWOT・財務情報
    United Company RUSAL Plc - Strategy, SWOT and Corporate Finance Report Summary United Company RUSAL Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Orbit International Corp.:企業の戦略・SWOT・財務情報
    Orbit International Corp. - Strategy, SWOT and Corporate Finance Report Summary Orbit International Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Wilbur-Ellis Holdings Inc:企業の戦略的SWOT分析
    Wilbur-Ellis Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Intrum Justitia AB:企業のM&A・事業提携・投資動向
    Intrum Justitia AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Intrum Justitia AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Genalyte Inc-医療機器分野:企業M&A・提携分析
    Summary Genalyte Inc (Genalyte) is a healthcare service provider that develops cancer biomarker panels and testing platforms for screening. The company provides technologies such as the Maverick Detection System and Silicon Photonics Biosensor technology. Its Maverick Detection System quantifies the …
  • Cochlear Ltd (COH):企業の製品パイプライン分析
    Summary Cochlear Ltd (Cochlear) is a medical device company that offers implantable hearing solutions. It develops, manufactures and markets electronic implantable hearing devices. The company’s products are suited for people with hearing loss caused by ear nerve damage. Its major products include c …
  • Amplyx Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Amplyx Pharmaceuticals Inc (Amplyx) is a developer of antifungal medicines. The company develops antifungal agents for the treatment of life-threatening invasive fungal infections due to candidia, aspergillus and rare molds. It also develops small molecule therapy APX001, which is in clinica …
  • B. Braun Melsungen AG:医療機器:M&Aディール及び事業提携情報
    Summary B. Braun Melsungen AG (B. Braun) develops, manufactures and distributes medical technology and pharmaceutical products, and provides medical services worldwide. The company’s major products include solutions and disposables for infusion, nutrition and pain therapy, infusion pumps and systems …
  • Ambrx Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ambrx Inc (Ambrx) is a biopharmaceutical company that offers discovery and development of protein-based medicines by using its expanded genetic code. The company provides pipeline product candidate’s portfolio such as ARX618 FGF21, PSMA ADC, CD70 ADC and Anti-CD3 X Folate. It develops pipeli …
  • BASF India Ltd (BASF):企業の財務・戦略的SWOT分析
    Summary BASF India Ltd (BASF) a subsidiary of BASF SE is a chemical company that manufactures and distributes specialty chemicals, performance products, plastics and crop protection products. The company’s chemical products include intermediates, monomers and petrochemicals. Its performance products …
  • Young & Co.’s Brewery plc (YNGA):企業の財務・戦略的SWOT分析
    Young & Co.'s Brewery plc (YNGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Atopix Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Atopix Therapeutics Ltd (Atopix) is a clinical stage biotechnology company that develops novel treatments for Th2-mediated eosinophilic asthma. The company’s product portfolio includes CRTH2 used in the treatment of atopic dermatitis. It also offers ATX2417 and OC459 used in treatment of ast …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆